Efficacy and cost-effectiveness of consensus interferon monotherapy with high-dose induction for hepatitis C patients with genotype 2

References

• Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41–52.
   PubMed Web of Science ®Google Scholar
• Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006;130:231–64.
   PubMed Web of Science ®Google Scholar
• Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303–13.
   PubMed Web of Science ®Google Scholar
• Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147–71.
   PubMed Web of Science ®Google Scholar
• Fattovich G, Zagni I, Minola E, Felder M, Rovere P, Carlotto A, A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C. J Hepatol 2003;39:843–9.
   PubMedGoogle Scholar
• Heathcote EJ, Keeffe EB, Lee SS, Feinman SV, Tong MJ, Reddy KR, Re-treatment of chronic hepatitis C with consensus interferon. Hepatology 1998;27:1136–43.
   PubMed Web of Science ®Google Scholar
• Jensen DM, Krawitt EL, Keeffe EB, Hollinger FB, James SP, Mullen K, Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration. Consensus Interferon Study Group. Am J Gastroenterol 1999;94:3583–8.
   PubMedGoogle Scholar
• Keeffe EB, Hollinger FB. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group. Hepatology 1997;26:101S–107S.
   Google Scholar
• Sjogren MH, Sjogren R, Holtzmuller K, Winston B, Butterfield B, Drake S, Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C. Dig Dis Sci 2005;50:727–32.
   PubMedGoogle Scholar
• Suzuki H, Tango T. A multicenter, randomized, controlled clinical trial of interferon alfacon-1 in comparison with lymphoblastoid interferon-alpha in patients with high-titer chronic hepatitis C virus infection. Hepatol Res 2002;22:1–12.
   PubMedGoogle Scholar
• Tong MJ, Blatt LM, Resser KJ, Klein MC, Cruickshank SE, Figueroa T, Treatment of chronic hepatitis C virus infection with recombinant consensus interferon. J Interferon Cytokine Res 1998;18:81–6.
   PubMedGoogle Scholar
• Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keeffe EB, Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. Hepatology 1997;26:747–54.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997;26:2S–10S.
   Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales Jr FL, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975–82.
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958–65.
   PubMed Web of Science ®Google Scholar
• Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992;73:673–9.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Tsukiyama-Kohara K, Yamaguchi K, Yagi S, Tanaka S, Hasegawa A, Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology 1994;19:1347–53.
   PubMed Web of Science ®Google Scholar
• Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N, Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology 1997;113:558–66.
   PubMed Web of Science ®Google Scholar
• Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513–20.
   PubMed Web of Science ®Google Scholar
• Del Rio RA, Post AB, Singer ME. Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. Hepatology 2006;44:1598–1606.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999;30:1318–24.
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sette Jr H, Morgan TR, Balan V, Diago M, Marcellin P, Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346–55.
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485–92.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40:993–9.
   PubMed Web of Science ®Google Scholar
• Arias E. United States life tables, 2006. Natl Vital Stat Rep 2010;58:1–40.
   Google Scholar
• Gold MR, Siegel JE, Russell LB, Weinstein MC Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
   Google Scholar
• Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997;127:855–65.
   PubMed Web of Science ®Google Scholar
• Singer ME, Younossi ZM. Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. Am J Med 2001;111:667–8.
   PubMedGoogle Scholar
• Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA 1998;280:2088–93.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Boparai N, McCormick M, Price LL, Guyatt G. Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastroenterol 2001;96:579–83.
   PubMed Web of Science ®Google Scholar
• Chong CA, Gulamhussein A, Heathcote EJ, Lilly L, Sherman M, Naglie G, Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003;98:630–8.
   PubMed Web of Science ®Google Scholar
• Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003;52:425–32.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Iino S, Omata M, Kumada H, Hino K. Efficacy of interferon alfacon-1 daily induction therapy followed by three-times weekly therapy in patients with chronic hepatitis C virus infection with high and low viral titers. Hepatol Res 1999;15:64–79.
   Google Scholar
• Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426–32.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (10–12 June 2002). Gastroenterology 2002;123:2082–99.
   PubMedGoogle Scholar
• Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1493–9.
   PubMed Web of Science ®Google Scholar
• Iwasaki Y, Ikeda H, Araki Y, Osawa T, Kita K, Ando M, Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006;43:54–63.
   Google Scholar
• Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463–72.
   PubMed Web of Science ®Google Scholar
• Kim WR, Poterucha JJ, Hermans JE, Therneau TM, Dickson ER, Evans RW, Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 1997;127:866–74.
   PubMed Web of Science ®Google Scholar
• Krahn M, Wong JB, Heathcote J, Scully L, Seeff L. Estimating the prognosis of hepatitis C patients infected by transfusion in Canada between 1986 and 1990. Med Decis Making 2004;24:20–9.
   PubMed Web of Science ®Google Scholar
• Ascher NL, Lake JR, Emond J, Roberts J. Liver transplantation for hepatitis C virus-related cirrhosis. Hepatology 1994;20:24S–27S.
   PubMed Web of Science ®Google Scholar
• Detre KM, Belle SH, Lombardero M. Liver transplantation for chronic viral hepatitis. Viral Hepatitis Rev 1996;2:219–28.
   Web of Science ®Google Scholar
• Kilpe VE, Krakauer H, Wren RE. An analysis of liver transplant experience from 37 transplant centers as reported to Medicare. Transplantation 1993;56:554–61.
   PubMed Web of Science ®Google Scholar
• Roberts MS, Angus DC, Bryce CL, Valenta Z, Weissfeld L. Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database. Liver Transpl 2004;10:908–10.
   PubMedGoogle Scholar
• Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991;325:729–31.
   PubMedGoogle Scholar
• Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;329:1896–7.
   Google Scholar